Gelonghui, May 11 | Huadong Pharmaceutical (000963.SZ) said on an interactive platform that the company has been deeply involved in the field of industrial microbiology for more than 40 years and has a deep industrial base and industrial transformation capabilities. The company established a subsidiary Huida Biotech in 2020 as the company's industrial microbial technology innovation platform, and acquired Nannong Dongyao in April 2023 to quickly enter the field of animal protection. The company's industrial microbiology focuses on the two major business scenarios of synthetic biology technology system application and biomedical innovation and development, and has formed differentiated product pipelines and business solutions in the four major fields of xRNA, specialty APIs & intermediates, health & biomaterials, and animal health care.
华东医药(000963.SZ)：公司工业微生物聚焦于合成生物学技术系统应用和生物医药创新发展两大业务场景
East China Pharmaceutical (000963.SZ): The company's industrial microbiology focuses on two major business scenarios: the application of synthetic biology technology systems and biomedical innovation and development
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.